share_log

The Past Five Years for Avanos Medical (NYSE:AVNS) Investors Has Not Been Profitable

The Past Five Years for Avanos Medical (NYSE:AVNS) Investors Has Not Been Profitable

Avanos Medical(纽约证券交易所代码:AVNS)投资者在过去五年中一直没有盈利
Simply Wall St ·  02/23 10:03

Generally speaking long term investing is the way to go. But along the way some stocks are going to perform badly. For example the Avanos Medical, Inc. (NYSE:AVNS) share price dropped 58% over five years. We certainly feel for shareholders who bought near the top. We also note that the stock has performed poorly over the last year, with the share price down 33%.

一般而言,长期投资是必经之路。但在此过程中,一些股票将表现不佳。例如,阿瓦诺斯医疗公司(纽约证券交易所代码:AVNS)的股价在五年内下跌了58%。对于在接近顶部买入的股东,我们当然有同感。我们还注意到,该股去年表现不佳,股价下跌了33%。

Now let's have a look at the company's fundamentals, and see if the long term shareholder return has matched the performance of the underlying business.

现在让我们来看看公司的基本面,看看长期股东回报是否与基础业务的表现相匹配。

Because Avanos Medical made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

由于Avanos Medical在过去十二个月中出现了亏损,因此我们认为至少目前市场可能更加关注收入和收入增长。一般而言,没有利润的公司预计每年收入将增长,而且速度很快。可以想象,收入的快速增长如果持续下去,通常会带来利润的快速增长。

In the last half decade, Avanos Medical saw its revenue increase by 2.5% per year. That's not a very high growth rate considering it doesn't make profits. It's likely this weak growth has contributed to an annualised return of 10% for the last five years. We want to see an acceleration of revenue growth (or profits) before showing much interest in this one. However, it's possible too many in the market will ignore it, and there may be an opportunity if it starts to recover down the track.

在过去的五年中,Avanos Medical的收入每年增长2.5%。考虑到它没有盈利,这不是一个很高的增长率。这种疲软的增长很可能使过去五年的年化回报率达到10%。在对此表现出浓厚兴趣之前,我们希望看到收入(或利润)的加速增长。但是,市场上可能有太多人会忽略它,如果它开始复苏,可能会有机会。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以在下面看到收入和收入如何随着时间的推移而变化(点击图片了解确切的值)。

earnings-and-revenue-growth
NYSE:AVNS Earnings and Revenue Growth February 23rd 2024
纽约证券交易所:AVNS收益和收入增长 2024年2月23日

Take a more thorough look at Avanos Medical's financial health with this free report on its balance sheet.

通过这份免费的资产负债表报告,更全面地了解Avanos Medical的财务状况。

A Different Perspective

不同的视角

While the broader market gained around 26% in the last year, Avanos Medical shareholders lost 33%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 10% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. You could get a better understanding of Avanos Medical's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

尽管去年整个市场上涨了约26%,但Avanos Medical的股东却下跌了33%。即使是优质股票的股价有时也会下跌,但我们希望在过于感兴趣之前看到企业基本指标的改善。不幸的是,去年的表现可能预示着尚未解决的挑战,因为它比过去五年中10%的年化亏损还要糟糕。总的来说,长期股价疲软可能是一个坏兆头,尽管逆势投资者可能希望研究该股以期出现转机。通过查看这张更详细的收益、收入和现金流历史图表,您可以更好地了解Avanos Medical的增长。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

如果你想与管理层一起购买股票,那么你可能会喜欢这份免费的公司名单。(提示:业内人士一直在购买它们)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发